{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T18:48:14Z","timestamp":1778006894639,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1136\/annrheumdis-2013-203819","type":"journal-article","created":{"date-parts":[[2013,8,13]],"date-time":"2013-08-13T01:11:41Z","timestamp":1376356301000},"page":"2010-2021","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?"],"prefix":"10.1016","volume":"73","author":[{"given":"Polina","family":"Putrik","sequence":"first","affiliation":[]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[]},{"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[]},{"given":"Tuulikki","family":"Sokka","sequence":"additional","affiliation":[]},{"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[]},{"given":"Annelies","family":"Boonen","sequence":"additional","affiliation":[]},{"given":"Ledio","family":"Collaku","sequence":"additional","affiliation":[]},{"given":"Ruzanna","family":"Harutyunyan","sequence":"additional","affiliation":[]},{"given":"Helga","family":"Radner","sequence":"additional","affiliation":[]},{"given":"Nikolay","family":"Soroka","sequence":"additional","affiliation":[]},{"given":"Herman","family":"Mielants","sequence":"additional","affiliation":[]},{"given":"Sekib","family":"Sokolovic","sequence":"additional","affiliation":[]},{"given":"Lyubomir","family":"Sapundzhiev","sequence":"additional","affiliation":[]},{"given":"Miroslav","family":"Mayer","sequence":"additional","affiliation":[]},{"given":"Paraskevi","family":"Charalambous","sequence":"additional","affiliation":[]},{"given":"Jiri","family":"Vencovsky","sequence":"additional","affiliation":[]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[]},{"given":"T\u00f5nu","family":"Peets","sequence":"additional","affiliation":[]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[]},{"given":"Khatuna","family":"Letsveridze","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[]},{"given":"M\u00e1rta","family":"P\u00e9ntek","sequence":"additional","affiliation":[]},{"given":"Gerdur","family":"Gr\u00f6ndal","sequence":"additional","affiliation":[]},{"given":"Fiona","family":"McGrehan","sequence":"additional","affiliation":[]},{"given":"Seriolo","family":"Bruno","sequence":"additional","affiliation":[]},{"given":"Togizbayev","family":"Galymzhan","sequence":"additional","affiliation":[]},{"given":"Daina","family":"Andersone","sequence":"additional","affiliation":[]},{"given":"Irena","family":"Butrimiene","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Hirsch","sequence":"additional","affiliation":[]},{"given":"Snezana","family":"Misevska-Percinkova","sequence":"additional","affiliation":[]},{"given":"Karen","family":"Cassar","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Deseatnicova","sequence":"additional","affiliation":[]},{"given":"Dusan","family":"Mustur","sequence":"additional","affiliation":[]},{"given":"Filip","family":"Raciborski","sequence":"additional","affiliation":[]},{"given":"Viviana","family":"Tavares","sequence":"additional","affiliation":[]},{"given":"Florian","family":"Berghea","sequence":"additional","affiliation":[]},{"given":"Ivan","family":"Shirinsky","sequence":"additional","affiliation":[]},{"given":"Miodrag","family":"Veljkovic","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Kovarova","sequence":"additional","affiliation":[]},{"given":"Matija","family":"Tomsic","sequence":"additional","affiliation":[]},{"given":"Francisca","family":"Sivera","sequence":"additional","affiliation":[]},{"given":"Ingemar","family":"Petersson","sequence":"additional","affiliation":[]},{"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[]},{"given":"Shaydullo","family":"Sharipov","sequence":"additional","affiliation":[]},{"given":"Nevsun","family":"Inanc","sequence":"additional","affiliation":[]},{"given":"Tatyana","family":"Dumenko","sequence":"additional","affiliation":[]},{"given":"Suzanne","family":"Verstappen","sequence":"additional","affiliation":[]},{"given":"Hojimurad","family":"Khudoberdiev","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2013-203819_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/JOM.0b013e3181de8357","article-title":"Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab","volume":"52","author":"Herenius","year":"2010","journal-title":"J Occup Environ Med"},{"key":"10.1136\/annrheumdis-2013-203819_bib2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs"},{"key":"10.1136\/annrheumdis-2013-203819_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10198-003-0223-0","article-title":"Out-patient drug policy by clinical assessment rather than financial constraints? The gate-keeping function of the out-patient drug reimbursement system in The Netherlands","volume":"5","author":"Pronk","year":"2004","journal-title":"Eur J Health Econ"},{"key":"10.1136\/annrheumdis-2013-203819_bib4","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","author":"Putrik","year":"201473198","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-203819_bib5","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1136\/ard.2009.109983","article-title":"Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST RA database","volume":"68","author":"Sokka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-203819_bib6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/ard.2008.100362","article-title":"Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe","volume":"68","author":"Emery","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-203819_bib7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-203819_bib8","unstructured":"The World Bank. [cited 2011 October 26th]; http:\/\/www.worldbank.org\/."},{"key":"10.1136\/annrheumdis-2013-203819_bib9","unstructured":"European health for all database (HFA-DB). [cited 26th October 2011]; http:\/\/data.euro.who.int\/hfadb\/."},{"key":"10.1136\/annrheumdis-2013-203819_bib10","unstructured":"European Comission (EUROSTAT). [cited 26th October2011]; http:\/\/epp.eurostat.ec.europa.eu\/portal\/page\/portal\/eurostat\/home\/."},{"key":"10.1136\/annrheumdis-2013-203819_bib11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-203819_bib12","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","article-title":"QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-203819_bib13","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1148\/radiol.2273011499","article-title":"Correlation and simple linear regression","volume":"227","author":"Zou","year":"2003","journal-title":"Radiology"},{"key":"10.1136\/annrheumdis-2013-203819_bib14","first-page":"21","article-title":"Do we need guidelines to stop as well as to start biological therapies for rheumatoid arthritis?","volume":"30","author":"van den Broek","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2013-203819_bib15","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-203819_bib16","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2013-203819_bib17","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.semarthrit.2010.09.004","article-title":"Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy","volume":"41","author":"Pease","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2013-203819_bib18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/03009742.2010.493895","article-title":"Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009","volume":"40","author":"Neovius","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/annrheumdis-2013-203819_bib19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.healthpol.2010.11.006","article-title":"An even smaller area variation: differing practice patterns among interventional cardiologists within a single high volume tertiary cardiac centre","volume":"104","author":"Mercuri","year":"2012","journal-title":"Health Policy"},{"key":"10.1136\/annrheumdis-2013-203819_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.berh.2012.07.011","article-title":"Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid arthritis (RA): Lessons from QUEST RA","volume":"26","author":"Putrik","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2013-203819_bib21","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.3310\/hta8060","article-title":"Effectiveness and efficiency of guideline dissemination and implementation strategies","volume":"8","author":"Grimshaw","year":"2004","journal-title":"Health Technol Assess"},{"key":"10.1136\/annrheumdis-2013-203819_bib22","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/rheumatology\/ker270","article-title":"Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide","volume":"50","author":"van den Berg","year":"2011","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2013-203819_bib23","first-page":"220","article-title":"Use of biological therapies in rheumatoid arthritis management: a comparison between the main worldwide and Brazilian recommendations","volume":"51","author":"Fernandes","year":"2011","journal-title":"Rev Bras Reumatol"},{"key":"10.1136\/annrheumdis-2013-203819_bib24","series-title":"Initiative Arznei&Vernunft Vern\u00fcnftiger Umgang mit Medikamenten in Rheumatoider Arthritis","year":"2012"},{"key":"10.1136\/annrheumdis-2013-203819_bib25","unstructured":"Erstattungskodex des \u00f6sterreichischen Hauptverbandes."},{"key":"10.1136\/annrheumdis-2013-203819_bib26","unstructured":"Guidelines treatment with disease modifying drugs in RA\/Consensus-statement for B-cell modifying drugs\/for T-cell modifying drugs National Austrian League of Rheumatology, 2006 (DMARDs RA) 2008 (B-cells)\/2009 (T-cells)."},{"key":"10.1136\/annrheumdis-2013-203819_bib27","unstructured":"RIZIV (Rijksinstituut Ziekteverzekering), 2001 (updated in 2010)."},{"key":"10.1136\/annrheumdis-2013-203819_bib28","series-title":"National guidelines for treatment of rheumatoid arthritis with biologic DMARDs, Bulgarian Scientific Society in Rheumatology","year":"2008"},{"key":"10.1136\/annrheumdis-2013-203819_bib29","series-title":"Recommendation for use of TNF blocking drugs in rheumatoid arthritis, Croatian Society for Rheumatology","year":"2007"},{"key":"10.1136\/annrheumdis-2013-203819_bib30","first-page":"29","article-title":"[Proposal for biologic drugs therapy in rheumatoid arthritis]","volume":"57","author":"Curkovic","year":"2010","journal-title":"Reumatizam"},{"key":"10.1136\/annrheumdis-2013-203819_bib31","series-title":"Odluka o utvr\u0111ivanju Osnovne liste, lijekova Hrvatskog zavoda za zdravstveno osiguranje","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib32","series-title":"A modified version of NICE guidelines, Cyprus Society for Rheumatology & Pharmaceutical Services of the Ministry of Health","year":"2007"},{"key":"10.1136\/annrheumdis-2013-203819_bib33","first-page":"146","article-title":"Safety of biological therapy\u2014Guidelines of the Czech Society for Rheumatology","volume":"17","year":"2009","journal-title":"Ceska Revmatologie"},{"key":"10.1136\/annrheumdis-2013-203819_bib34","first-page":"182","article-title":"Recommendations of the Czech Society for Rheumatology for the treatment of rheumatoid arthritis","volume":"18","author":"Pavelka","year":"2010","journal-title":"Ceska Revmatologie"},{"key":"10.1136\/annrheumdis-2013-203819_bib35","unstructured":"Dansk Reumatologisk Selskabs kliniske retningslinje for klassifikation diagnostik, behandling og monitorering af reumatoid artritis (RA) 2012."},{"key":"10.1136\/annrheumdis-2013-203819_bib36","series-title":"Estonian RA guidelines","year":"2002"},{"key":"10.1136\/annrheumdis-2013-203819_bib37","unstructured":"Eesti Haigekassa tervishoiuteenuste loetelu. https:\/\/www.riigiteataja.ee\/akt\/122122011042, 2011."},{"key":"10.1136\/annrheumdis-2013-203819_bib38","series-title":"Suomalaisen L\u00e4\u00e4k\u00e4riseuran Duodecimin ja Suomen Reumatologisen yhdistyksen asettama ty\u00f6ryhm\u00e4 Nivelreuma P\u00e4ivitetty","year":"2009"},{"key":"10.1136\/annrheumdis-2013-203819_bib39","series-title":"Haute Autorit\u00e9 de Sant\u00e9","year":"2007"},{"key":"10.1136\/annrheumdis-2013-203819_bib40","first-page":"592","article-title":"[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]","volume":"71","author":"Kruger","year":"2012","journal-title":"Z Rheumatol"},{"key":"10.1136\/annrheumdis-2013-203819_bib41","first-page":"291","article-title":"Guidelines for the use of biological agent in the treatment of rheumatoid arthritis and spondyloarthritides","volume":"19","author":"Sidiropoulos","year":"2008","journal-title":"Hellenic Rheumatology"},{"key":"10.1136\/annrheumdis-2013-203819_bib42","series-title":"Kl\u00edn\u00edskar lei\u00f0beiningar um notkun TNF-\u03b1 blokkandi lyfja fyrir sj\u00faklinga me\u00f0 ikts\u00fdki (rheumatoid arthritis\/RA)","year":"2009"},{"key":"10.1136\/annrheumdis-2013-203819_bib43","first-page":"1503","article-title":"A Nemzeti Er\u0151forr\u00e1s Miniszt\u00e9rium szakmai protokollja az arthritisek kezel\u00e9s\u00e9r\u0151l szintetikus \u00e9s biol\u00f3giai betegs\u00e9gm\u00f3dos\u00edt\u00f3 gy\u00f3gyszerekkel","volume":"61","year":"2011","journal-title":"Eg\u00e9szs\u00e9g\u00fcgyi K\u00f6zl\u00f6ny"},{"key":"10.1136\/annrheumdis-2013-203819_bib44","series-title":"A rheumatoid arthritis diagnosztik\u00e1j\u00e1nak \u00e9s kezel\u00e9s\u00e9nek finansz\u00edroz\u00e1si protokollja (finansz\u00edroz\u00e1si elj\u00e1r\u00e1srend) Orvosszak\u00e9rt\u0151i \u00e9s Szakmai Ellen\u0151rz\u00e9si F\u0151oszt\u00e1ly","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib45","unstructured":"Unpublished Irish guidelines."},{"key":"10.1136\/annrheumdis-2013-203819_bib46","first-page":"7","article-title":"Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy","volume":"29","author":"Caporali","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2013-203819_bib47","series-title":"Biological disease-modifying antirheumatic drugs usage guidelines of autoimmune inflammatory arthritis in adults in Latvia Rheumatology society&Ministry of health","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib48","series-title":"Guidelines for the use of Tocilizumab, Lithuanian Rheumatologist Association","year":"2011"},{"key":"10.1136\/annrheumdis-2013-203819_bib49","series-title":"Guidelines for the use of TNF blockers, Lithuanian Rheumatologist Association","year":"2007"},{"key":"10.1136\/annrheumdis-2013-203819_bib50","series-title":"Guidelines for the use of Rituximab, Lithuanian Rheumatologist Association","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib51","unstructured":"Macedonian criteria for inclusion of patients on biological therapy. University Rheumatology Clinic - Skopje, Macedonian Association Against Rheumatism - MAAR."},{"key":"10.1136\/annrheumdis-2013-203819_bib52","unstructured":"Protocols for Etanercept, Infliximab and Rituximab."},{"key":"10.1136\/annrheumdis-2013-203819_bib53","series-title":"Recommendation for use of TNF blocking drugs in rheumatoid arthritis., Reumatoloski dani, Becici","article-title":"Montenegrin Society for Rheumatology and Montenegrin Section of Rheumatology","year":"2011"},{"key":"10.1136\/annrheumdis-2013-203819_bib54","series-title":"Use of biologicals, Nederlandsche Internisten Vereniging (NIV) Reumapati\u00ebntenbond with support of Afdeling Ondersteuning Professionele Kwaliteit van de Orde van Medisch Specialisten","article-title":"Dutch Society for Rheumatology in collabortation with Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV), Nederlands Genootschap van Maag-Darm-Leverartsen (NGMDL), Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT)","year":"2003"},{"key":"10.1136\/annrheumdis-2013-203819_bib55","series-title":"Revidert utgave februar","article-title":"Nasjonale faglige retningslinjer for bruk av TNF-\u03b1 hemmere og andre biologiske betennelsesdempende legemidler innen revmatologi god","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib56","series-title":"Official translations of the EULAR recommendations, Medycyna Praktyczna","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib57","unstructured":"Portuguese Society for Rheumatology. Portuguese Guidelines for the Use of Biological Agents in Rheumatoid Arthritis. http:\/\/www.spreumatologia.pt, Acta Reumatol Port, 2003."},{"key":"10.1136\/annrheumdis-2013-203819_bib58","series-title":"Internal use guidelines, Speciality Consultative Commissions of the Ministry of Health (MofH)","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib59","series-title":"Rheumatoid arthritis, national guideline for physicions in primary health protection","article-title":"Medical association of physicions, Rheumatology society","year":"2005"},{"key":"10.1136\/annrheumdis-2013-203819_bib60","series-title":"Criteria of the Commission of the Republic Health Insurance Fund for approving the use and provision, The Ministry of Health Republic of Serbia, Medical association of physicions","article-title":"Rheumatoid arthritis, national guideline for physicions in primary health protection","year":"2005"},{"key":"10.1136\/annrheumdis-2013-203819_bib61","series-title":"The EULAR recommendations for RA management with synthetic and biological DMARDS (translated into Slovak language with permission of prof. Josef Smolen and the editors of Annals of Rheumatic Diseases)","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib62","series-title":"Biorx.si, Rheumatology society","year":"2008"},{"key":"10.1136\/annrheumdis-2013-203819_bib63","series-title":"Practice Guideline for RA (GUIPCAR), Spanish Society for Rheumatology (Sociedad Espa\u00f1ola de Reumatologia; SER)","year":"2011"},{"key":"10.1136\/annrheumdis-2013-203819_bib64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.reuma.2009.10.006","article-title":"Actualizacion del documento de consenso de la Sociedad Espa\u00f1ola de Reumatolog\u00eda sobre el uso de terapias biol\u00f3gicas en la artritis reumatoide","volume":"6","author":"Tornero Molina","year":"2010","journal-title":"Reumatol Clin"},{"key":"10.1136\/annrheumdis-2013-203819_bib65","series-title":"Nationella riktlinjer f\u00f6r r\u00f6relseorganens sjukdomar. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit St\u00f6d f\u00f6r styrning och ledning","year":"2012"},{"key":"10.1136\/annrheumdis-2013-203819_bib66","unstructured":"The National guidelines for Musculoskeletal Diseases 2012\u2014summary (http:\/\/www.socialstyrelsen.se, ), 2012."},{"key":"10.1136\/annrheumdis-2013-203819_bib67","unstructured":"Swissmedic-Registration 55184 (http:\/\/www.swissmedic.ch\/, )."},{"key":"10.1136\/annrheumdis-2013-203819_bib68","series-title":"Compendium Suisse des M\u00e9dicaments 2011 Remicade, Documed SA","year":"2011"},{"key":"10.1136\/annrheumdis-2013-203819_bib69","unstructured":"List of medical preparations (http:\/\/bag.e-mediat.net\/SL2007.Web.External\/ShowPreparations.aspx, ), The Federal Health Agency (BAG), 2007."},{"key":"10.1136\/annrheumdis-2013-203819_bib70","series-title":"Reimbursement rules, Ministry of Labour and Social Security","year":"2011"},{"key":"10.1136\/annrheumdis-2013-203819_bib71","series-title":"National Institute for Health and Clinical Excellence","article-title":"NICE guidance on biologic drugs for the treatment of rheumatoid arthritis","year":"2010"},{"key":"10.1136\/annrheumdis-2013-203819_bib72","series-title":"BSR Principles for Biologic Prescribing, The British Society for Reumatology","year":"2010"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724098261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724098261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2013-203819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T23:47:20Z","timestamp":1737244040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724098261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0003496724098261"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-203819","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2013-203819","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http:\/\/group.bmj.com\/group\/rights-licensing\/permissions. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}